Original news and analysis on international IP policy
A group of civil society organisations and health experts have sent a letter to delegates to this month’s annual World Health Assembly urging support for a study on the delinkage of the costs of research and development from the prices of cancer medicines. Member states reportedly met on the issue today and are still undecided.
The World Health Organization announced today that it will launch a pilot project in 2017 for prequalifying cancer biosimilar medicines, with the intent of lowering prices on some of the most expensive cancer treatments.
The Drugs for Neglected Diseases initiative (DNDi) has launched a collaborative project with five universities in India, United Kingdom, and the United States to help with the research on a debilitating neglected disease.
The World Health Organization Bulletin this month has an article about the need for new models of research and development for tuberculosis and antimicrobial resistance. The article describes a new funding framework called the 3P Project.
Cynthia Ho writes: In the first known investment dispute regarding patents, Eli Lilly & Co v. Canada, Canada recently prevailed over the pharmaceutical giant Eli Lilly. Although Canada won in a unanimous decision, the ruling does not, however, guarantee domestic discretion going forward, contrary to the suggestion of some.
The United States Department of Defense has announced that it intends to grant Sanofi Pasteur, a French pharmaceutical corporation, exclusive rights to develop a vaccine for the Zika virus. The decision follows outcry from the public and civil society groups over concerns of affordability and accessibility in taking such a step.
The Medicines Patent Pool has received a licence to develop ravidasvir, a new treatment for hepatitis C.
Hepatitis-related mortality is on the rise, despite the existence of an efficient vaccine for hepatitis B and a cure for hepatitis C, according to the World Health Organization hepatitis report 2017 published today. One of the issues is that a majority of people are unaware of their condition due to limited access to affordable hepatitis testing. The price of the hepatitis C medicines has decreased in low-income countries, but still remains a barrier in upper-middle income and high-income countries, the WHO said.
Five years after health institutions and actors including pharmaceutical companies endorsed the London Declaration on Neglected Tropical Diseases, meant to support the World Health Organization to control and eradicate 10 specific diseases by 2020, new commitments were announced today (18 April) in Geneva.
Global health matters are entering into the Group of Twenty (G20) agenda under the German presidency of the group, which started in December 2016. The first-ever G20 Health Ministers' meeting is scheduled to take place in May, before the regular G20 meeting in July. This week, a professor from the Graduate Institute of Geneva explained how health has become part of the G20 agenda.
With the looming threat of antimicrobial resistance (AMR), there is growing pressure to use vaccines because they obviate the need to prescribe antibiotics in the first place.
The World Health Organization has been recommended to provide details on its spending of funds provided to its pandemic influenza framework by the private sector.